The FDA on May 1 announced it cleared Medtronic’s Attain Stability Quad MRI SureScan left heart lead for commercial use in the U.S.

Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).

The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).

Heart disease might be the leading cause of death in the United States, but, according to a recent report, it’s also one of the least searched-for diseases on the internet.

Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.

Cardio-oncology has emerged as an area of rapid growth in the medical community in recent years, owing in large part to an increasing population of cancer survivors.

Stress disorders like PTSD and adjustment disorder were linked to adverse cardiovascular outcomes in a recent BMJ study, Reuters reports, with the greatest CV risk posed in the months directly after a patient is diagnosed with such a condition.

The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.

Supplementing standard physicals with Abbott’s high-sensitivity troponin-I blood test could boost the accuracy of CVD prediction in middle-aged patients, according to research published in Circulation April 29.

CMS saw an influx of public commentary after it first published a draft of recommendations for revising the United States’ national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) more than a month ago. Now that the 30-day comment period is over, the agency has a decision to make.